Status:
COMPLETED
The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis
Lead Sponsor:
Chengdu PLA General Hospital
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to access the effect (week 12/week 24) of puerarin injection on carotid intima-media thickness (CIMT) in rheumatoid arthritis (RA) patients despite routine anti-rheumatic ...
Detailed Description
* Controlled, randomized trial * RA patients under routine anti-rheumatic care were randomized to receive the treatment with or without 400 mg puerarin injection * Assessments were made at entry, 12 a...
Eligibility Criteria
Inclusion
- patients with a definite diagnose of rheumatoid arthritis(RA) were included if they met the classification criteria for RA established by the American Rheumatism Association (ACR) and European League Against Rheumatism (EULAR) in 2010
- aged from 18 to 75 years
- without conflict to the written, informed consent signed prior to the enrollment
- no severe hepatic or renal disorders
- no known carotid artery stenosis
- no coagulation disorders
- no hypertension
Exclusion
- being in pregnancy, lactation period or under a pregnancy plan
- being allergic to the test drug
- not compatible for the trial medication
- without full legal capacity
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT02254655
Start Date
November 1 2013
End Date
November 1 2017
Last Update
January 17 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.